Moxifloxacin-Loaded Lipidic Nanoparticles for Antimicrobial Efficacy

Area of Science:

• Pharmaceutical Nanotechnology
• Antimicrobial Drug Delivery

Background:

• Pulmonary infections pose a growing health challenge with limited therapeutic options.
• Liposomes, biodegradable and stable lipidic vesicles, offer advantages for drug delivery.

Purpose of the Study:

• To develop a novel liposomal moxifloxacin formulation.
• To evaluate its enhanced antimicrobial efficacy against key respiratory pathogens.

Main Methods:

• Liposomal moxifloxacin prepared via thin-film hydration with phospholipid and cholesterol.
• Cationic liposomes incorporated a cationic agent (CTAB).
• Vesicle size, surface charge, and Minimum Inhibitory Concentration (MIC) were determined.

Main Results:

• Liposomes ranged from 50-70 nm with a zeta potential of +22 mV for cationic vesicles.
• Liposomal moxifloxacin showed lower MIC values against both pathogens compared to free drug.
• Cationic liposomal moxifloxacin exhibited superior activity, with MICs of 2.5 µg/mL for P. aeruginosa and 0.5 µg/mL for S. aureus.

Conclusions:

• Encapsulating moxifloxacin in liposomes enhances its antimicrobial properties.
• Cationic liposomal formulations demonstrate significantly improved efficacy.
• This approach presents a promising strategy for treating pulmonary infections.